1. Home
  2. FMN vs LUNG Comparison

FMN vs LUNG Comparison

Compare FMN & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Federated Hermes Premier Municipal Income Fund

FMN

Federated Hermes Premier Municipal Income Fund

HOLD

Current Price

$11.06

Market Cap

87.8M

Sector

Finance

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.40

Market Cap

72.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FMN
LUNG
Founded
2002
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
87.8M
72.2M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
FMN
LUNG
Price
$11.06
$1.40
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
21.5K
670.5K
Earning Date
01-01-0001
03-04-2026
Dividend Yield
3.86%
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$6.20
Revenue Next Year
N/A
$21.61
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$10.11
$1.31
52 Week High
$11.38
$7.97

Technical Indicators

Market Signals
Indicator
FMN
LUNG
Relative Strength Index (RSI) 34.78 39.02
Support Level $10.97 N/A
Resistance Level $11.10 $2.01
Average True Range (ATR) 0.12 0.18
MACD -0.02 -0.02
Stochastic Oscillator 33.33 3.16

Price Performance

Historical Comparison
FMN
LUNG

About FMN Federated Hermes Premier Municipal Income Fund

Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: